An interventional study of Electronic Health Record Review and External Beam Radiation Therapy in Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm and Unresectable Solid Tumor, sponsored by Mayo Clinic. Recruiting at 2 sites in United States. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment
This clinical trial evaluates whether adding spatially fractionated radiation therapy (SFRT) to standard palliative external beam radiation therapy (EBRT) improves disease-related symptoms in patients with solid tumors that cannot be removed by surgery (unresectable). SFRT, originally termed GRID therapy, is a radiation therapy technique designed to deliver a highly uneven dose of radiation to a tumor. This is achieved by using a grid-like pattern, where isolated regions receive high doses, while the spaces between experience significantly lower doses. This method allows for a greater total dose to be delivered to the tumor while potentially reducing damage to surrounding healthy tissues. EBRT is a type of radiation therapy that uses a machine to aim high-energy rays at the cancer from outside of the body. Adding SFRT to standard palliative EBRT may improve disease-related symptoms such as pain, difficulty breathing, bleeding, or difficulty swallowing in patients with unresectable solid tumors.
3,514 studies on the registry are indexed under Neoplasm Metastasis; 883 are open to participants now.
This study's planned enrollment of 100 is above the median of 54 across 2,765 interventional studies indexed under Neoplasm Metastasis.
Browse Neoplasm Metastasis studies →Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.
Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Any of the following are excluded because this study involves ionizing radiation:
Patients undergo a single fraction of SFRT. Starting 1-3 days after SFRT, patients undergo standard palliative EBRT in a dose regimen determined by the treating physician.
Other: Electronic Health Record Review · Radiation: External Beam Radiation Therapy · Other: Questionnaire Administration · Radiation: Spatially-fractionated Radiation Therapy
Patients undergo standard palliative EBRT in a dose regimen determined by the treating physician.
Other: Electronic Health Record Review · Radiation: External Beam Radiation Therapy · Other: Questionnaire Administration
Ancillary studies
Undergo standard palliative EBRT
Also known as: Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation
Ancillary studies
Undergo SFRT
Also known as: GRID Therapy, SFRT, Spatially Fractionated Radiation Therapy
Response at 1 month - Patient-reported Impression of Change
Participants rate the most prominent symptom related to the target lesion to be treated on a 7-point scale ranging from -3 (very much worse) to +3 (very much better). Response will be reported as a binary yes/no, defined as a patient reporting that the symptom is moderately better or very much better 1 month after completing treatment.
Time frame: Baseline to 1 month follow-up
Change in Patient-reported Most Prominent Symptom Intensity
Participants will record the severity of the most prominent symptom related to the target lesion (e.g., pain, dyspnea, hemorrhage, dysphagia) using an 11-point Likert scale ranging from 0 (none) to 10 (unbearable). A between-group comparison of the magnitude of the severity scores will be made.
Time frame: Baseline to 1 month follow-up
Response at 3 months - Patient-reported Impression of Change
Participants rate the most prominent symptom related to the target lesion to be treated on a 7-point scale ranging from -3 (very much worse) to +3 (very much better). Response will be reported as a binary yes/no, defined as a patient reporting that the symptom is moderately better or very much better 3 months after completing treatment.
Time frame: At 3 month follow-up
Radiographic tumor response
Radiographic tumor response at 3 months post-treatment will be assessed by a modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Radiographic tumor response will be coded as a 1 if the patient meets the complete response (CR) or partial response (PR) modified RECIST criteria and 0 otherwise. Per the modified RECIST criteria, CR will be defined as disappearance of the target lesion, PR will be defined as ≥30% decrease in longest diameter (LD) of target lesion as compared to baseline measurement, Progressive Disease (PD) will be defined as ≥20% increase in LD of target lesion as compared to baseline measurement, and Stable Disease (SD) will be defined as not meeting the criteria for CR, PR, or PD.
Time frame: At 3 month follow-up
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mayo Clinic